|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2008-12-3
|
|
pubmed:abstractText |
The nucleoside analogue fludarabine is used in the treatment of chronic lymphocytic leukemia. It triggers p53-mediated apoptosis, although the mutational status of p53 does not fully account for heterogeneity in responsiveness to treatment. The aim of this study was to identify new genes implicated in fludarabine action as well as to determine the role of equilibrative nucleoside transporters (ENT) in the transcriptomic response triggered by this drug in chronic lymphocytic leukemia cells bearing wild type p53.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
93
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1843-51
|
|
pubmed:meshHeading |
pubmed-meshheading:18945750-Adult,
pubmed-meshheading:18945750-Aged,
pubmed-meshheading:18945750-Aged, 80 and over,
pubmed-meshheading:18945750-Equilibrative-Nucleoside Transporter 2,
pubmed-meshheading:18945750-Female,
pubmed-meshheading:18945750-Gene Expression Profiling,
pubmed-meshheading:18945750-Humans,
pubmed-meshheading:18945750-Intracellular Signaling Peptides and Proteins,
pubmed-meshheading:18945750-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:18945750-Male,
pubmed-meshheading:18945750-Middle Aged,
pubmed-meshheading:18945750-Tumor Cells, Cultured,
pubmed-meshheading:18945750-Vidarabine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
|
|
pubmed:affiliation |
Unitat d'Hematopatologia, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
